FDA ruling on Pfizer’s COVID jab for kids could come in November
[ad_1]
WASHINGTON (Reuters) – U.S. health regulators’ decision on whether to approve Pfizer (NYSE:) and BioNTech’s COVID-19 vaccine for children ages 5 to 11 could spill over into November if needed, the nation’s top u.s. infectious disease official said on Wednesday.
When Dr. Anthony Fauci was asked about Wall Street Journal reports that an expanded approval might not be forthcoming next month, he said that the Food and Drug Administration is working quickly and that “if that goes into November that’s because that’s what it’s needed.”
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.
[ad_2]